$EKSO
EKSO BIONICS HOLDINGS, INC.

2022 Q1 Form 10-Q Financial Statement

#000154908422000019 Filed on April 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $2.567M $1.910M
YoY Change 34.4% 30.11%
Cost Of Revenue $1.358M $675.0K
YoY Change 101.19% -18.77%
Gross Profit $1.209M $1.235M
YoY Change -2.11% 93.88%
Gross Profit Margin 47.1% 64.66%
Selling, General & Admin $4.447M $3.771M
YoY Change 17.93% -19.89%
% of Gross Profit 367.82% 305.34%
Research & Development $999.0K $603.0K
YoY Change 65.67% -15.19%
% of Gross Profit 82.63% 48.83%
Depreciation & Amortization $131.0K $126.0K
YoY Change 3.97% -23.17%
% of Gross Profit 10.84% 10.2%
Operating Expenses $5.446M $4.374M
YoY Change 24.51% -19.27%
Operating Profit -$4.237M -$3.139M
YoY Change 34.98% -34.34%
Interest Expense $27.00K $26.00K
YoY Change 3.85% -50.0%
% of Operating Profit
Other Income/Expense, Net -$383.0K -$531.0K
YoY Change -27.87% -123.63%
Pretax Income -$4.620M -$3.670M
YoY Change 25.89% 45.06%
Income Tax
% Of Pretax Income
Net Earnings -$4.620M -$3.670M
YoY Change 25.89% 44.83%
Net Earnings / Revenue -179.98% -192.15%
Basic Earnings Per Share -$0.36 -$0.34
Diluted Earnings Per Share -$0.36 -$0.34
COMMON SHARES
Basic Shares Outstanding 12.73M shares 10.75M shares
Diluted Shares Outstanding 12.73M shares 10.75M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.18M $49.54M
YoY Change -26.98% 481.46%
Cash & Equivalents $36.18M $49.54M
Short-Term Investments
Other Short-Term Assets $829.0K $640.0K
YoY Change 29.53% 56.1%
Inventory $2.772M $2.154M
Prepaid Expenses
Receivables $3.346M $2.276M
Other Receivables $0.00 $0.00
Total Short-Term Assets $43.12M $54.61M
YoY Change -21.03% 288.32%
LONG-TERM ASSETS
Property, Plant & Equipment $886.0K $1.096M
YoY Change -19.16% -28.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $141.0K $235.0K
YoY Change -40.0% 29.12%
Total Long-Term Assets $1.119M $1.899M
YoY Change -41.07% -34.11%
TOTAL ASSETS
Total Short-Term Assets $43.12M $54.61M
Total Long-Term Assets $1.119M $1.899M
Total Assets $44.24M $56.50M
YoY Change -21.7% 233.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.939M $1.652M
YoY Change 77.91% -17.36%
Accrued Expenses $1.819M $1.475M
YoY Change 23.32% -14.04%
Deferred Revenue $1.115M $1.493M
YoY Change -25.32% 21.28%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $5.970M $5.981M
YoY Change -0.18% -20.78%
LONG-TERM LIABILITIES
Long-Term Debt $1.994M $1.990M
YoY Change 0.2%
Other Long-Term Liabilities $60.00K $42.00K
YoY Change 42.86% -6.67%
Total Long-Term Liabilities $2.054M $2.032M
YoY Change 1.08% 4415.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.970M $5.981M
Total Long-Term Liabilities $2.054M $2.032M
Total Liabilities $10.76M $15.53M
YoY Change -30.74% 32.55%
SHAREHOLDERS EQUITY
Retained Earnings -$213.5M -$202.8M
YoY Change 5.28% 9.13%
Common Stock $13.00K $13.00K
YoY Change 0.0% 116.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.49M $40.98M
YoY Change
Total Liabilities & Shareholders Equity $44.24M $56.50M
YoY Change -21.7% 233.47%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$4.620M -$3.670M
YoY Change 25.89% 44.83%
Depreciation, Depletion And Amortization $131.0K $126.0K
YoY Change 3.97% -23.17%
Cash From Operating Activities -$4.206M -$2.000M
YoY Change 110.3% 16.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $37.30M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 $38.71M
YoY Change -100.0% -6672.5%
NET CHANGE
Cash From Operating Activities -$4.206M -$2.000M
Cash From Investing Activities $0.00
Cash From Financing Activities $0.00 $38.71M
Net Change In Cash -$4.230M $36.68M
YoY Change -111.53% -1656.75%
FREE CASH FLOW
Cash From Operating Activities -$4.206M -$2.000M
Capital Expenditures $0.00
Free Cash Flow -$4.206M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Ekso Bionics Holdings, Inc.
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001549084
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37854
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0367049
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1414 Harbour Way South
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1201
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Richmond
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94804
CY2022Q1 dei City Area Code
CityAreaCode
510
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
984-1761
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
EKSO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12844501 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36176000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40406000 USD
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
19000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
28000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3346000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4662000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
2772000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
2242000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
829000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
485000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
43123000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47795000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
886000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
991000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
92000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1819000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1115000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1220000 USD
CY2022Q1 us-gaap Assets
Assets
44242000 USD
CY2021Q4 us-gaap Assets
Assets
49166000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2939000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3107000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
97000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5970000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6855000 USD
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1082000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1475000 USD
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
1994000 USD
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1993000 USD
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1650000 USD
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1550000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
60000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
10756000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
11947000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12844000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12844000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12693000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12693000 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
246765000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
246090000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1358000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
195000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213487000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208867000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33486000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37219000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44242000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49166000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2567000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
675000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
1209000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
1235000 USD
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1629000 USD
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1793000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
999000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
603000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2818000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1978000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5446000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
4374000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4237000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3139000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
27000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
26000 USD
CY2022Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-100000 USD
CY2021Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
11000 USD
CY2022Q1 ekso Other Income Expense
OtherIncomeExpense
-256000 USD
CY2021Q1 ekso Other Income Expense
OtherIncomeExpense
-516000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-383000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-531000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4620000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
212000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
465000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4408000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3205000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12728000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12728000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10752000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10752000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37219000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4620000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
176000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
499000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
212000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33486000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35360000 USD
CY2021Q1 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3878000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
152000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
356000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
465000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
40975000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4620000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
131000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
126000 USD
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-9000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
31000 USD
CY2022Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-100000 USD
CY2021Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
11000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
499000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
356000 USD
CY2022Q1 ekso Common Stock Contribution
CommonStockContribution
64000 USD
CY2021Q1 ekso Common Stock Contribution
CommonStockContribution
52000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-254000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-503000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1297000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-917000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
562000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
228000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
203000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
78000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-166000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
151000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-503000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16000 USD
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-488000 USD
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-165000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4206000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2000000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37295000 USD
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38712000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-24000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4230000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36677000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40406000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36176000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49539000 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
27000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
23000 USD
CY2022Q1 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
0 USD
CY2021Q1 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
1936000 USD
CY2022Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
CY2021Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2461000 USD
CY2022Q1 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
29000 USD
CY2021Q1 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
53000 USD
CY2022Q1 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
176000 USD
CY2021Q1 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
152000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213487000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4206000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36176000 USD
CY2022Q1 ekso Debt Covenant Covenant Compliance Unrestricted Cash
DebtCovenantCovenantComplianceUnrestrictedCash
2000000 USD
CY2022Q1 ekso Unrestricted Cash
UnrestrictedCash
34176000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of March 31, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div>
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
212000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
465000 USD
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2218000 USD
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2061000 USD
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
308000 USD
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
145000 USD
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
246000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
36000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
2772000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
2242000 USD
CY2022Q1 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2124000 USD
CY2021Q4 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2349000 USD
CY2022Q1 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
0 USD
CY2021Q4 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
280000 USD
CY2022Q1 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
73000 USD
CY2021Q4 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
66000 USD
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2197000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2695000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1115000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1220000 USD
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1082000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1475000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2695000 USD
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2197000 USD
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
142000 USD
CY2022Q1 ekso Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
196000 USD
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
694000 USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2197000 USD
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
902000 USD
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
681000 USD
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
614000 USD
CY2022Q1 ekso Contractwith Customer Liability Non Cancellable Backlog
ContractwithCustomerLiabilityNonCancellableBacklog
1524000 USD
CY2022Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2021Q4 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
280000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2567000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1520000 USD
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
132000 USD
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12844000 shares
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2015000 USD
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
226000 USD
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
73000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1819000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36176000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000 USD
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2000000 USD
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
6000 USD
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
1994000 USD
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1994000 USD
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
1994000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
98000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
98000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
97000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y2M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12844000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12693000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12693000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1240000 shares
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2022Q1 ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0 shares
CY2022Q1 ekso Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1240000 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
499000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
356000 USD
CY2022Q1 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
176000 USD
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2022Q1 ekso Common Stock Contribution
CommonStockContribution
64000 USD
CY2021Q1 ekso Common Stock Contribution
CommonStockContribution
52000 USD
CY2022Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000 USD
CY2022Q1 us-gaap Contractual Obligation
ContractualObligation
3460000 USD
CY2021Q4 us-gaap Contractual Obligation
ContractualObligation
1446000 USD
CY2022Q1 ekso Lessee Operating Lease Lease Not Yet Commenced
LesseeOperatingLeaseLeaseNotYetCommenced
227000 USD
CY2022Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P3Y
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4620000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4620000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3670000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3670000 USD
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12728000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12728000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10752000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10752000 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2270000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2087000 shares
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2567000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1358000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
1209000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
675000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
1235000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2567000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD

Files In Submission

Name View Source Status
0001549084-22-000019-index-headers.html Edgar Link pending
0001549084-22-000019-index.html Edgar Link pending
0001549084-22-000019.txt Edgar Link pending
0001549084-22-000019-xbrl.zip Edgar Link pending
ekso-20220331.htm Edgar Link pending
ekso-20220331.xsd Edgar Link pending
ekso-20220331_cal.xml Edgar Link unprocessable
ekso-20220331_def.xml Edgar Link unprocessable
ekso-20220331_htm.xml Edgar Link completed
ekso-20220331_lab.xml Edgar Link unprocessable
ekso-20220331_pre.xml Edgar Link unprocessable
ekso-3312022xex311.htm Edgar Link pending
ekso-3312022xex312.htm Edgar Link pending
ekso-3312022xex321.htm Edgar Link pending
ekso-3312022xex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending